FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 658 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Detecting multiple cancers with a ‘simple’ blood test: Where are we? April 14, 2022 Reflections from the World Cancer Congress November 30, 2022 FDA Approves New Dosing Regimen for Cetuximab April 13, 2021 Inspired By Her Mom’s Breast Cancer Battle, Girl Sells ‘Cancer Bears’... March 11, 2021 Load more HOT NEWS Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer? How to Provide Support as a Long-Distance Cancer Caregiver FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma Identical Twins Find Strength in Shared Breast Cancer Battle After Being...
